All News

World Health Organization Director-General Tedros Ghebreyesus said there are 7 or 8 top vaccine candidates for coronavirus disease 2019 (COVID-19); hydroxychloroquine alone, or paired with azithromycin, showed no benefit for hospitalized patients with severe cases of COVID-19; the reported death toll from COVID-19 surpassed 80,000 yesterday, with a CDC report suggesting that thousands of unreported New York City deaths may be linked to the virus.

The FDA approved Eli Lilly’s selpercatinib (Retevmo) capsules to treat non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other thyroid cancer tumors. The treatment is indicated for patients whose tumors have an alternation, such as a mutation or fusion, in a specific gene (RET or 'rearranged during transfection'), marking the first approval of a therapy for cancer patients with the RET gene alterations.

The nation’s top infectious disease expert, Anthony Fauci, MD, and other health officials are entering various levels of quarantine after potential exposure to coronavirus disease 2019 (COVID-19); the National Institute of Allergy and Infectious Diseases details how and why it halted a study on remdesivir in patients with COVID-19 early; the president’s economic advisers project rising unemployment rates.

Testing will now be possible for those who cannot get to a collection center, including those who are home because they are ill, quarantined, or at high risk of infection due to their age or comorbidities. A Rutgers official said the new method will allow for a dramatic increase in the number of people who can be tested.

This week, the top managed care news included FDA grants emergency use authorization to COVID-19 treatment; dapagliflozin’s new approval breaks ground in SGLT2 competition; and AJMC® gets an inside look at how The Michael J. Fox Foundation is assisting the Parkinson community during the pandemic.

Guidelines created by the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) address care management and treatment options for patients with psoriasis in relation to the increased risk of developing inflammatory, cardiovascular, and metabolic conditions.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo